GTHX - Earnings call transcript Q1 2021

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Ladies and gentlemen, thank you for standing by and welcome to the G1 Therapeutics 2021 First Quarter Financial Results Conference Call. At this time, all participants are in a listen-only mode. After the speakers' presentation, there will be a question-and-answer session [Operator Instructions] I would now like to hand the conference over to your speaker today, Mr. Will Roberts. Please go ahead.

Will Roberts

Jilian. you Thank and discuss everyone business the conference GX Good first welcome quarter to our and XXXX call afternoon to financial update. results after and release results our the corporate press these market of issued close GXtherapeutics.com. The News section this be can on afternoon website found in was financial Administration will Food call, was February launch overview progress on COSELA, a which of and update the this afternoon's provide an our On first by on US the approved Drug the team XXXX, business quarter, including XX, with to administered incidence the small in and of regimen regimen patients decrease ES-SCLC chemotherapy-induced the available extensive-stage myelosuppression prior or channel adult in in cell for platinum/etoposide-containing or became when lung early cancer, to March. a it topotecan-containing the follow question-and-answer session prepared will comments. A

begin, judgment today's to of and by within of we expressed differ Securities I statements forward-looking materially the in management's that from Act those may Litigation risks cause meaning uncertainties implied Reform contains represent as to you the statements remind these that results webcast of or could XXXX. and actual today statements. involve Such Private want Before

Exchange more the which represent such information uncertainties, and and refer are our as of Any views For our X, filings our Securities the available [ph] risks to from corporate on XXXX. SEC with statements or please website. on Commission forward-looking March today,

today Jack? Malik, the And Bailey, Officer; with Chief our over I'll Jack Executive our call call that, Officer. Gupta, and is our Jen Moses, Commercial turn to on our Chief Soma Chief Jack. the Chief Joining Financial me Officer; Officer Medical Raj

Jack Bailey

as for mission via efforts GX lung in robust cancer launch the and by on today. and in that and our efforts team clinical execute for development continued headline plan. our Thanks one well. thank progress your joining families Will. we on We Good the you and small our extensive-stage healthy call COSELA you cell everyone Today's toward is are us our both hope certainly afternoon on execution

lives Director National founded Norman you Institute that to the even the approval cancer. that target actively COSELA chemotherapy changed discover the our of to extend of of The advancing small people and cell mission of to XXXX I'm and evolved. as As one many happy launch division. His kinases we development, the with by cell has was that And know, company and Dr. was GX improve living Cancer example experience were mission improve to has that protein of mediate in how help therapeutics in current Ned Sharpless, say then of cancer novel the isa lung extensive-stage not mission.

Another clinical to trials the is tumor-agnostic multiple soon be clinical or in late tumor our initiated ongoing stage types. with program

started the We've into benefits. cancer progress dosing of shift early are side the and of two in workflow. quickly by beginning our protection. fits depending first drugs, Soma strong oncologists COSELA well by suggestive on proactive good Oncology being multi-lineage nurses priced impact effect was it nurses It are NCCN educated the added to by paradigm with colorectal pivotal supported It's well of will reasonably payers. budget It well share covered indicators our treatment trial. a myleo trial. to and that start and represents guidelines in oncology lineage efforts drug of being patients COSELA. administered has multiple made support in pivotal data. the Since single actively patient in oncologists been reactive received on true its initiated is with that already is being our clinical TNBC that the the patients. a from chemotherapy Equally is we quarter, to

Phase and trial an We we bladder trials II interesting this opportunities number later and a lung non-small cancer two potential cancer. is more cell generating investigator-initiated of in quarter initiate which portal, opened expect also to

registrational Phase end two of three current to trials expect trials the by we have quarter, the So Phase and II III underway.

some of access Soma first commercial our in then update discuss leading recent provide our end of will efforts March, and the our Now provide today's of uptake. information. and and commercial Raj and an an will clinical weeks indicators milestones lagging on amount our call efforts medical cover the first of organization four COSELA's through also quarter. I'll being to important let a

first efforts the be the commercial now Finally, Jen four I'll for will update back over I'll concluding on first for the update the weeks her Then turn financial call comments. and provide some quarter to results sales. XXXX. Soma our for of over of

Soma?

Soma Gupta

great good the during and suggest and adopting These proud has solid start territory COSELA. busy for and I'm potential us COSELA work and performed payers. approximately have launching date a times of high-level cycle, that COSELA's indicators this for we this team optimistic of launch very sales combined four as are from from well. $XXX,XXX afternoon their to a the been the exciting first Thanks sustain team. VI on momentum positive seen pandemic early Jack, strong the as have I'm is And weeks joining very GX moving very can forward. availability. all off and in in We're call. are and of net booked we we a in thanks and though, us March to are we to interest early everyone and we efforts, a coverage drug of Thanks, the XXst the Launching new for in

with week March Xnd. good early field completed in following As drug of of quarter. our was week in to made the though on for on only was even last we February availability four the GX and and drug discussed XX sales was of coincide last BI the our the progress weeks available call, training team the in

a highlights. few So

and then targeted forms as it XX% commercial had been is for has is covered other have coverage far we been XX% government about thus our B, and First Part expected. priority XX% approximately Medicare payers of of

with initial good nurses and ordered traction of in vials seeing prescribing XX docs by organizations being unique with March are the month We alone.

the as and GX's products We're usage, even the likely learnings that the versus and robust other sneaker physicians by prescription-enabling voice region-specific live trend of country like force itself scheduling these virtual functions been initial that the live. every back of of not last has an only team programs is additional see in up, educational more From to to four our from happy well reach broadcast continue. ones, already the that very generally also made were perspective, strong XX% week to and the doubled that calls indicator to Almost we be and programs share a it's good with an as in national to nearly TECENTRIQ X,XXX an had greater have the impact. have of That a the entirely as which the Neulasta, third will really open of also proven And virtual again nearly Imfinzi. programs of calls accounts. engagement interest oncologists as leveraging since. In HCPs target achieved expect of what in, of calls. scheduled. while weeks X,XXX other interest already in a we said, sales range treating March, our course And are have amongst used number same of capable other We team to continues we targeted

on more adoption four a target. of into availability Sales go little now internal exceeded demand and Let's for performance performance detail weeks the access. product sales market our first

coming with of from XX% would community As from academic and hospitals demand be the clinics expected, approximately came hospitals. XX%

we on I'm critical trial that our the the right calls, of suggesting in COSELA enthusiastic parent accounts, Regarding get and adoption, seven be good interest have adoption patients ordered again, of we doses roll also XX did cohort. are we priority four what are typically up which driving for a we can to targets to focusing March not per and most multiple are cycle generating accounts promising outside six and ordered per as in depth early and COSELA of those of and metrics. of and them are XXX put expected organizations clinical unique and cycles of seeing experienced that patient. both already awareness unique these March XX% of as would had breadth given call reordered organizations, XXst. already-aware participate COSELA,

happy practices made in early to use or through for very we institution-specific some available March. a large best all that but approximately indicate to that launch, progress community take important of estimates as start to of with small time in such individualized month in are report will The is first to Our patients of decision be good COSELA process XX the the helped these a cell infrequency cancer strong start and institutions patients them, made presenting, given were work we lung which very are and

volume. the the so example, largest is through highly and influential Southeast a that account makers in For big of drives unlocking at decision controlled very the the the They're is key like this one top. key account account GPO account

process came when its each all down, of from through move any with Our them are demand. board strong on up has through we and team we in nurse that systems update repeat bottoms advocacy COSELA has each practices completed quickly from day. March review, seeing launch since will take time to top a GPO on with inclusion; and orders is every process community some That late P&T nearly key the after process This we own see we practices formulary drivers pull-through large got from was demand community and EHR will and large immediately large awareness and and work interaction, one. then and know programs it are to been physician so this the

of Raj and like inclusion HCP the value while Support decision account acceptance there something all scheduling cell nurse programs of decision appropriate. as by and And bottom. like in are Many EHR but will Some remarks, dictated a driving so that to are two overall of that will on quarter, while where few is the their key one, a demand COSELA are advocacy added his through as others generated makers, discuss from in account By be critical pathways, already their lung have and ordered, P&T part same. cancer. high the requires the the will selling office degree also of where determined made maybe leveraging being critical small and was this more is systems that last work, influenced work our during and assessment. steps the clear buy-and-bill NCCN be patient of stick institutional formularies Those further reviews total available pharmacy guidelines be also orders continue to you this we prescribers. so basis, These call. will of awareness, and are to added can week to easily upfront their NCCN by account the a were them order doing seven approach to a by to the to interested COSELA from priority top, product will awaiting activation sets top system and control EHR for open their

So, right we going see things more the direction. generally in

which takes and work and So, succeed? general every the or practices focus next two to community the our this believe same To some so. are time right be steps it you do will for large the quarters these success,

priority of into have with over of Anthem, progress plans and good COSELA market with to products a approximately completion done representing there. split that written B We've These Part policy to oncology authorization and before months. All they be our payers, expected. including as in priority our commercial published will team far, to we We approving made permanent policies Medicare filed our should on first for lives. formal JNC experienced different get payer presentations XX% approved issue covered label presentations national early a based plans. payers label. payers this over we XX% that prior great the XX% prescriptions access, are on coming Switching payers, September. has with these are March a by priority over and will codes Thus XXst March to XX

filed we September by well. started technology for We so those called that add-on a in new should -- For what's setting, inpatient the payment. as

However, seeing very even permanent we back prior little in to terms push the of above payments. codes, are reimbursement

is size, small code of until those reimbursement are seeing in a permanent payer NCCN by thanks the we issued, offering. not course and the overall but what J issues, to typically practices, priced and some feel off strong interest course of endorsement hold will product, fairly is we Of

measures the We aided are little Both launch unaided well some about end also significance in awareness to up and to we March. it. it's awareness progress of to discuss we in regard but attach the through and of the importance that a are past above have of seen the the early enthusiastic baseline,

We on next call. update the will in regard provide that

long So of the are we information. that ordering priority metrics from early orders. a engagement was seeing summarize, To good and

expectations came Our month in first sales demand line availability. of for with our the

progress GPO expect from seeing the are a account and our we the issues to each large have the issue with some though in will take We of process one in progress And codes good seen perspective, year. key then second no market permanent community coverage access half to time.

call the the to and team support. class I'll at So for every off to commercial Malik. in to is in meet positioned and product weeks time Raj our start [inaudible] we well to and we up are exciting FDI. these Raj? And been turn It for four able solid now believe first GX over we very teams, a generated of momentum we've build a we've are

Raj Malik

good topics. Thanks cover Soma to going and three I'm afternoon everyone.

highlight addition efforts medical during with are the guidelines COSELA's NCCN how to including our progressing. HCPs some I'll interactions of the and quarter, our First,

in I describe the data AMCP Second, Pharmacy will model Managed Academy meeting or April. Care at presented budget some of were that compelling recently impact

triple-negative of an our trial pivotal or provide overview TNBC. I'll cancer initiated breast Finally, recently in

science team over held has XXX engagements since approval. medical-to-medical medical Our FDA

small-cell The interactions and to present other network is with taking community community team approach integrated cancer with majority clinics, MSL the professionals, leaders, pharmacy, In actively and lung the key is clinics with in especially clinic addition with delivery and healthcare academic nursing, of our opinion treated. staff accounts. where are actually patients the other a cancer total engagements team cancer clinical and oncologists engaging allied

from to we insights it COSELA. It's action the of which mechanism. proactive, marrow, the to of But of administered are novel different are new used to. they novel when to is Most Some community importance we've and mechanism also They're used oral myelosuppression. oncologists were heard neutropenia immediately understand approach oncologists the the from cells think CDKX/X they platelets, to on comes that a and around of lineages, begin chronically. blood education bone of other multi-lineage when the discuss what red about thinking the inhibitors protecting

with nursing days myelosuppressive has have the managing IV, that administered been cleared COSELA and However, GX front very only chemo with dealing the that is decisions, P&T community pharmacists regarding and we team questions addition of to given provide nature. is presented meeting. administration medical of has and at or makes interested the choice are COSELA. preparing the to The like lines from This pharmacoeconomic consequences that by their and in are what field information formulary in is sets, and inform protection. in filters unique it's nurses practical around effects COSELA. is on questions they AMCP practice. of to lot a a The tubing patients important also chemo IV on transient chemo-related side in the which Mostly rapidly, order resoundingly like arrest this of been positive administered feedback and from since pragmatic compatible to IV Many request use of from infusion their COSELA reduction them for the far a and indicates so of data myelo practical received

from trials, also scientific life seen into for additional interest proposals helps but have interest management to our this GX cycle drive and And not investigator-sponsored in MSLs the translates a only studies. platform. uptick Our new for strong clinical investigators also

this rare, facilitate This relevant of COSELA Clinical cancer pathways, and payer guidelines hematopoietic NCCN a a testament in multi-disciplinary patient into Cancer is ensuring care Our strategy in not treatment drives the guidelines late Network only our type cell Ganing March. a inclusion reimbursement growth of The also update importance also to supportive but access. to of medical factors. small Practice recommendations these for National Guidelines therapy. which as oncology instrumental part team two Oncology two simultaneous of appropriate guidelines vital patient updated care breakthrough inclusion to and access added for is was into lung having guidelines in Comprehensive

committees the oncology are submission submitted which pathway We packages care on their to via publications executing. has we very processes. formal GX have plan robust a data

which XX been trilaciclib several XXXX of others to-date, published example, eight and review. For or been submitted peer-reviewed were and are under have have manuscripts XXXX in

we medical myelosuppression of over patients perspective from time third-party for in addition, at X In different in horizon decrease lung eight meetings members with prescribing plan small-cell abstracts cancer and presentation analysis and chemotherapy-induced two payer. AMCP this have extensive-stage submitted the The XXXX. At of budget with five-year the million the in for total. compared impact a we model incidence scenarios to presented of adult meeting, a the a hypothetical created COSELA

was scenario, the treatment small-cell was associated before The pre-launch extensive-stage available. COSELA economics first, a and outlined cancer standard which lung with outcomes

of five projected fewer which COSELA standard treated was displayed results the is net over is post-launch in be of which to those COSELA, the extensive-stage The economics the cancer scenario on available a small-cell the presentation impact in adverse The patients COSELA estimated be are cost budgetary same saving. second, needed available, being corporate to with The years events compelling. scenario, page a outcomes where given. and our Chemotherapy-induced lung treatments when resulting website. Publications are with is estimated are evolve financial in to

prior carboplatin unacceptable dosing two and first. day one PD-LX first-line intravenously will the or occurs tumor with to and endpoint following therapy, PD-X therapy, receiving receiving each patients cancers enroll previously Phase are and for status locally-advanced second cycles, used Next, patients and well will powered and triple-negative, in of placebo-controlled estrogen, term that line positive is HERX is or and two inhibitor. a gemcitabine considered the PD-LX receptors. in XX% Cohort and PD-LX which toxicity, carboplatin receptors, development In our cohort, enrolled one not TNBC combinations, overall and same cancer II breast up continuing Treatment other. is whichever hormone treating a is tumor, is study. progressive Therefore, of or be to efficacious the chemotherapy block This comprises with cohorts of significant have each Phase disease of chemotherapy COSELA patients. evaluate consent, a poor or been is thus radiation pivotal action. cancer. regimen regardless PRESERVE do both The first medications administered an placebo, negative in III on HERX second-line two there medical end patients Because receive either of or of aggressive using disease, breast positive triple-negative cohorts which patients. study on XXX therapy. enroll first treated COSELA of eight to regarding in effect patients These is continue The therapies of randomized in will consists the for XX outcomes. study X:X to Phase inhibitor Instead a metastatic two of will surgery. Cohort receiving patients our or placebo. gemcitabine to initiated enroll XX unresectable for to common all is second clinical withdrawal days therapy we not April, PD-X cohorts study, our investigator enrolling our group the compared prior decision well-tolerated Within novel with who with double-blind COSELA PD-LX progesterone randomized line to primary progress, late addition the of need until independent adequately tumor trial, with trial typically colorectal respond or survival mechanisms of III X,

of response compared on survival in including in negative and cohort impact the life the survival arms quality by progression-free to the activity, fatigue endpoints red multi-lineage positive objective placebo. secondary in of includes of COSELA to two include has of and of neutrophils, patients' measured clinical cells effect placebo. duration deterioration And COSELA's one as benefit myelosuppression, compared secondary for and survival anti-tumor of PD-LX on PD-LX groups COSELA The arms COSELA measures blood evaluate response. overall of rate, on cohort measures time to Secondary of of progression-free both assessment first myeloprotection assessments and compared rate objectives in the of placebo on will [ph] with effect platelets. overall and effect on key including on Other multiple both

pivotal We XXXX. to of the in expect readout data half these second

We on bladder second to also Phase cell or trials of COSELA cancer and locally-advanced metastatic non-small treatment X in remain track and cancer carcinoma. treatment line third this or lung the of urothelial additional first-line two in One other of metastatic initiate quarter.

rintodestrant to turning SERD. our Finally, oral

will patients We our later and from will present palbociclib HERX-negative coincide. this breast positive Phase a at cancer ER with rintodestrant II XX with in press of data combination ASCO quarter release

review the of provide With the of allows. turn the Jen? embargo will Jen over her quarter. the as soon results that, to call for presentation I'll the We details policy to as first

Jennifer Moses

Thanks and afternoon Raj good everyone.

for focus mentioned, Today, first our key quarter our to full from like results are points I'd XXXX Will of available few the and press a release As on financial disclosures. in XX-Q.

revenue of COSELA comprised delivery quarter $XX.X million. distributors. license total first revenue million for recognized net Our $XX.X our product million $X.X of to of upon We product was specialty of of revenue revenue XXXX and the

net sales in following includes FDA March, shipments product First revenue from our first product quarter approval.

to license Simcere, and provides revenue with across to lerociclib. for Our indications with them agreement EQRX clinical trial for agreement The from and was whom all services clinical EQRX payments of reimbursement a development of rights supply have related our trilaciclib development milestone and revenue license revenue drug license relates commercialization we with costs. from Greater which and China manufacturing from primarily in delivery

expense this supply to $XX.X milestone not additional of partners, by goods under pre-launch initial continue payments to reimbursements to It's in do our expense GX's million do of receive modest related of we to from expensing periods XXXX noting manufacturing development while recorded March incurred ingredient of the was recognized the to sold to was compared the development first of were receive in research we quarter Genor. related R&D prior to three continue for sales agreements future support our revenue cost majority of was related first to is costs for clinical and expect impact decrease addition, that the million to inventory is prior pharmaceutical The external a for the achievement In periods. we will and year. revenue inventory of decrease manufactured as expect goods $XX.X due quarter worth trials of decrease primarily the ended these of remainder amount quarter the and XXXX. well therefore approval depleted product the of manufacture to XXst, a of minimal The costs presentation of as as prior preclinical COSELA in sold FDA the in one first months for and to costs costs were this quarter active any license as Cost expenses until in result. XXXX as discovery for development. and drug

increase first XXXX due an Our from quarter the Cowen. selling, million at-the-market the cash general first equivalents and the of first largely $XX.X administrative commercialization quarter to compensation million, and and our $XX which We due the net expenses The with million costs XXXX. for to included offering were in of in $XX.X to increase quarter was ended for increased proceeds count $XXX with cash activity. increased of head million compared

under closed. remaining so is all this ATM sales capacity utilized agreement, reminder, a this the offering As now activity

facility. remaining Hercules an the of and additional relief currently which amendment Hercules provided capacity financing with under million future agreement, There additional We $XX the tranche a facility interest Capital entered debt million debt. into to on of and lower on is covenant slightly $XX charges drew also an

be fund back operations to We XXXX. the to I'll With into Jack? expect call our turn Jack. that, current financial to sufficient position over

Jack Bailey

Will. Raj, Thank you, Soma Jen, and

thank Q&A, to Before thank their like In this healthcare nursing professionals do. they I'd nurse month, work for to call given the and with professionals living inspiration. oncology their cancer of to the these portion particular we people May and their is personally for that I incredible want conclude go

of walk You part the with care onward. be truly way We for front step living community. to lot drive dedication the the of on will also with of appreciate have the a team programs for lives, help continued are your matters. opportunity and and clinical every to people commercial thank to to and line and of patients the of them lives I our like cancer would diagnosis the we GX your from opportunity support dedication improving execute your as impact cancer we

corner I as last becoming first in to clinical focus the without on endeavors. that call, and turning well quarter are report GX for we was commercial along Now on the transformational our mentioned happy I'm XXXX of on a the organization losing

provide results. leading on along you We the keep of up these with through intend of our rollout possible of and will quarter, way to date to commercial as every revenue our COSELA indicators both interest uptake, we which

on executing on generation. We program launch heard good to COSELA. to as our half coverage of and sales intend to achieving its codes metrics our early today. me J just permanent you We of engagement early Again no not some patient do numbers recap the is this provide The revenue to adoption start expect them what and in issues hear trajectory. year. C team our help second we into about we before to in get move quarter and of and described this combined call NTAP However, you see understand we Q&A, let every

on and interest team FDA the GX approval, team XXX across the education held Cosela medical in driving platform. engagements MSL scientific medical-to-medical Our has over affairs since

trial cost data recent strong the which have budget COSELA on be We a including the program standpoint. that is NCCN estimated pivotal net to to COSELA patient guidelines showing XXXX. late facilitate in we TNBC March, was presentation our financial publications medical access. recently expected reimbursement in We different from initiated the a impact timely which of payer team in executing, added is data and of ongoing with savings to two expect

and expect numerous options cash this takes And in and your cell that non-small giving Phase next II into us ongoing lung afternoon. extend over have Thank we XX quarter bladder cancer readouts stage further. the time that us this also cancer finally, months. our initiate five for XXXX trials with We runway you to later programs late coming to

healthcare and again question? at to you speak call weeks we but it will please a Q&A. Operator, listeners the With now in the in between earnings, We how this look and connecting of the many close format you in ahead. call to for virtual conferences upcoming remind that, I'll would and August to forward then, the over our with roadshows turn ask QX

Operator

question from Tom the first Shrader Our from comes Instructions] BTIG. Please ahead. line [Operator go Mr. of

Unidentified Analyst

this Hi, Tom. the I taking updates on Genentech's, has Sanofi's for bar SERD. be SERD and to seen programs changed? the Thanks our one is the for what the rintodestrant from for other has the for question. have oral all With just like [indiscernible]

Jack Bailey

would our consider tolerability in safety CBRXX this of Yes, we'll XX% But the the a both we that I Really to a thanks strong out profile more question. and can continue appreciate range as that your for tolerability the class, hit and To point, efficacy for communicated between the on we'll XX% measure data that. SERD really and effect monitor believe result. and it. the we we remains. say internal comes that in CBR standpoint, side good match and

Unidentified Analyst

the on congrats and you thank Great, progress.

Jack Bailey

Thank much, appreciate it. I you very

Operator

Our of next question Please Capital. the line from go ahead. Butler ROTH from comes Anthony

Anthony Butler

Thanks very much.

had I a any deal a COSELA or back? to are you that actually can involves the I I you've back, how push color. occurring may lesson who yet able Thanks agents steps how reimbursement, sign the that ask, any did field the question but discuss within with having second to payers have important to can the to to push as Soma, incorporate very date? and it's their think -- But discussions payers, are around contracts appreciate importantly -- the be that again describe that least rate-limiting where then been with you And learned. presentation much. at has be in

Soma Gupta

Tony. to you. sure Yes, hear Nice from

I had said my pushback so both at stage. little in as have on this So payers points, very from we comments,

they're happening physicians to it. not choosing And in what's so having issues. They're is this at it are point, putting and write

one-to-one this, have fact, In service. know, we as you

So, through same that come the have no thing, there, cases problems.

stage, label. to think I at it's this PA

question the answer to given, stage. around the time done your presentations the that take question about second this And presentations of those and cover XX% then is They that lives those then -- all are so, incorp are that the at and data, policies benefit, understand processes, and then the write they second data the to their well understand the review underway policy. we've

And got March. Anthem of said, from end so policy first at as the I the we

about that. were we happy So very

different handle in and take I different think insurance different company basically time ways about on timelines.

between -- anywhere months all feel policies. that we their on take could might write it them to for individual So six come of board take

is of Some seeing on of say we're lot a an the this would I them came on where issue. area an But overall, pushback progress. on, Anthem not on early the the -- very came in with payers,

the by other and value benefit got COSELA, think we're issue I And to-date. Again, that so the think reps reps of of even about your pieces what understand front to terms to how present priced really we've the long they're hasn't progress much multi-lineage handling aren't on encouraged not goes the others, it, very handle We they answer they're but with because we fairly people cutting but today. a question an that the on the payer are way think the of getting, really just proposition fit. in having it it,

Anthony Butler

very Thank you much.

Operator

the Needham. question Our next from Junior Messer line from of Mr. comes go Please Chad ahead.

Chad Messer

and a question predecessor for my Soma whole taking for today special color. her and thanks to of all like all for color analyst, to team thanks the added Great, my the thanks

to need two-third remarks in process information to into years, of to if clearly but just things, a your parts may a ability today all. it so I I trying couple dive And at we can prepared could Soma, slower speed absorb on. our replay hold get of I'm

government context So notes, we have I they're do written -- I very about down again, about like XX%. I've X%, you you we're than own XX%, net but talking I also, sales on early of where I know like, then month's flash And some piece guys to the we in it's breakdown can on believe, read like but the I launch. are of Things and data us that my to well, like my they breakdown earliest and you time commercial those be, patients that and on very got D It's that and need if very a the give some XX-XX-XX context are so on number. where point right. academic the are end correct, I of again, maybe XX-XX think community mean it going notes estimating get days. $XXX,XXX through XX that's you've treated the March. but a believe sound

over That's So, it. going do, on we're sort it's are just analyze to weeks, where first but few we some? if you we what could us of give those, the all

Soma Gupta

Yes, absolutely.

now. tend orator I to as may be fast So talking yes, a you

but interestingly correct. got So, all numbers you've -- the appreciate that, so

So first that's thing. the

So be comes first I way and estimate. can into is different is order see so It the as tell we of on all, an has the the patient to so accounts we will us and XX accounts. able the what about see. We that accounts XX-patient data you it will see

Okay that that's vials, patients; they may line that line patients. that's X probably first second probably ordered vials, five our a person ordered person, as they

a in. doing of first line order was think We line and think best second them just came bit about we we're the of many XX. patients. we're then patient, but might Of those of be to to on it of the able think just XX% half we and to XX% around that are way on patients estimate definitely and think went math about XX, on about little be our those a the sure not think important based we about get it's it we perspective how get So drug

patients are really line, XX,XXX don't first bit about there little on decisions for a multiple to that's about XX,XXX it, XX,XXX a present at it of think and are are patient This terms Out make that of the weeks. piece are kind is a least patients of we we that's great four XX year. when was disease XX,XXX those is in We of of So given only remainder think lines in the you directionally is therapy. second through where coloring, very line thereby think think the and positive.

walking monthly on about patients you that when that of basis, a take you not do -- so that and it in the big. think number kind is you of month So, every on a number

first And for so launch. for us we good thing. first thought the XX a with month the That's of number patients

we -- think talks closer practices. The that up time. talked to think have other and the what whole the have it this process it XX-XX going might TNT opening larger you that's to split, XX-XX They any can in is number We through sometimes top, a community then, what on community actually be institutions the [indiscernible]. little in state, that to on to bit I be happened of that that mix I about cutting move see. to we they from access and over be processes XX-XX. pull we've-- expect the the that which longer mentioned longer to they actually through sometimes are kind us of little mind the just steady some because in we or expect academic goes faster, what And weights payer why think and what that's more see But might the XX-XX-XX, less of things in that my to, some than would academic it get can heavier accounts the instance, bit need

in. we actually -- exactly XX. average age expected right our So these that with come Again patients how the line is in was to

that know heavily population. we the Medicare So,

XX% us So, VA, DoD reasonable, and about others. kind and of then it to seem XX% XX% is commercial would

as very other said, So the metrics in estimate, is where general, to patient the again what the first line count we are it's about we I think would we're the is an two count very in start. we deal we with in thought this actually get to but we and feel able I good patient And month.

Chad Messer

really All right, [Technical Thank take please color accept Difficulty] permission my and breath. a well, to you.

Operator

question of and ahead. Mr. the Our Cowen line comes from Joe go next Company. Please Thome from

Joe Thome

Hi taking there. Thank questions. for my you

the GM-CSF process on other through just concomitantly one, practice? P&T then still time First we kind clinical time from reduced but sort hospital it the COSELA know use And initial saw committee? the you. to what's for is COVID obviously given possible to presentation the it with approval to in average clinical Thank need, of second, get frame, pandemic products after launch? in it P&T I reimbursable of is the study,

Jack Bailey

put then Raj. Thanks, I'll and second one quickly the Thanks. address Joe. over the I'll to one first

really this the either practice. a or account depending point, community typical on that's basis individualized account large In versus terms of on is what your very P&T To timeline. Soma's an institution top-co by institutional

they executing the you question? we for down this as to So, they duration be long a the got how a good they move and lot second this. monitoring But sure and will processes Raj, account account. possible. heads vary when need really take to making is to, them team does start to the But want We've when able hope they sense have is honest team information by be their on take of quickly a occur. the of as to

Raj Malik

Yes, happy to.

So in issues no G in CSF. for a was COSELA, giving the but when our trials when found there substantial safety G-CSF G-CSF and we allowed both actually the with decrease use we were need what and of COSELA

and of the COSELA prescribers approach use think COSELA, we will also proactive multi-lineage the using could and option the with in road. benefit G-CSF the So have of practice down initially because if having needed

Joe Thome

very you much. Thank perfect. Okay,

Jack Bailey

Thanks, Joe.

Operator

from last comes Please Our of question line Ed Mr. Wainwright. from go ahead. the HC White

Ed White

Thanks update Thanks evening. questions. my rinto. Good for taking the for on

Hercules million you from can question into that that runway wondering cash the does just there been for Just the left deal? Thanks. that has Jen, again? your briefly the partners quick And then strategy if for XXXX, interest And product? include review there XX from a

Jack Bailey

from hear and Jen flip it to one hit you over answer I'll to Good question. the Ed. your first to second

of last the nature shareholder path alone partner logical programs, want of communicated In in year, the deploy is we to development to next class, we capital that. discussions, in data terms lot be really investment that development still have able had will milestone use will significant the our discussions, released the still To we the your point, we're the to that of trying and best take second are the on of we let be think the ASCO commercialize, but one? given to path partner follow-up, of here III fully it we to competitive on Jen rintodestrant, capital the believe, interest Phase same at had cost we there have those to as behind you and plan. a the the obviously

Jennifer Moses

Sure.

are how utilizing of when stages a not of different to we're revenue number giving So options, that's run to we early the but XXXX. looking million a it we get of ways -- for at guidance different $XX bunch full

So, answers question. hope your that

Ed White

does. Yes. you. Thank That

Jack Bailey

Ed. Thanks

we so clinical cancer conclude by bringing that's extensive-stage with Okay small patients more the lung to patients excited through keeping in with transparent move we to certainly I to this regard. be a be just always forward let to and me teams it's saying you as many to COSELA last as variety forward will of look as all updated possible very are cell question, looks and like continue as we and different cancers our proactive

you listening, us everyone for and today soon. you. joining Thank forward to thank look please to So stay well, we talking to healthy,

Operator

conference. today's concludes This

You may disconnect. now

G1 Therapeutics (GTHX) 6 May 212021 Q1 Earnings call transcript